{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:25:37Z","timestamp":1761823537061},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1093\/jjco\/hys215","type":"journal-article","created":{"date-parts":[[2013,1,5]],"date-time":"2013-01-05T03:15:56Z","timestamp":1357355756000},"page":"116-124","source":"Crossref","is-referenced-by-count":26,"title":["Current Therapeutic Strategy for Multiple Myeloma"],"prefix":"10.1093","volume":"43","author":[{"given":"Kenshi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,1,4]]},"reference":[{"key":"key\n\t\t\t\t20170511081657_HYS215C1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1126\/science.148.3668.376","article-title":"Myeloma proteins and the clinical response to Melphalan Therapy","volume":"148","author":"de Bergsagel","year":"1965","journal-title":"Science"},{"key":"key\n\t\t\t\t20170511081657_HYS215C2","first-page":"179","article-title":"Intermittent high dose prednisone therapy for multiple myeloma","volume":"51","author":"Salmon","year":"1967","journal-title":"Cancer Chemother Rep"},{"key":"key\n\t\t\t\t20170511081657_HYS215C3","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170511081657_HYS215C4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C6","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1158\/1078-0432.CCR-05-2305","article-title":"Intracellular protein degradation and its therapeutic implications","volume":"11","author":"Hideshima","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t20170511081657_HYS215C7","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C8","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2009.07803.x","article-title":"Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma","volume":"146","author":"Jagannath","year":"2009","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C10","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C11","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170511081657_HYS215C13","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.476.476","article-title":"Continued Overall Survival Benefit after 5 years\u2019 Follow-up with Bortezomib-melphalan-prednisone (VMP) Versus melphalan-prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and no Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial","author":"San Miguel","year":"2011"},{"key":"key\n\t\t\t\t20170511081657_HYS215C17","first-page":"1122","article-title":"A phase I\/II study of VMP as initial treatment for multiple myeloma in Japan","volume":"53","author":"Iida","year":"2012","journal-title":"Rinsho Ketsueki"},{"key":"key\n\t\t\t\t20170511081657_HYS215C18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","article-title":"The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma","volume":"143","author":"Niesvizky","year":"2008","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C19","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C20","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C22","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3324\/haematol.13285","article-title":"Prospective comparison of subcutaneous to intravenous administration of bortezomib in patients with multiple myeloma","volume":"93","author":"Moreau","year":"2008","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20170511081657_HYS215C23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20170511081657_HYS215C24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C26","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511081657_HYS215C27","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"Suppl. 1","key":"key\n\t\t\t\t20170511081657_HYS215C28","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","article-title":"Lenalidomide mode of action: linking bench and clinical findings","author":"Davies","year":"2010","journal-title":"Blood Rev."},{"key":"key\n\t\t\t\t20170511081657_HYS215C29","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C30","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170511081657_HYS215C31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","article-title":"Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response","volume":"154","author":"Lopez-Girona","year":"2011","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C32","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C33","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C34","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170511081657_HYS215C35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int J Cancer"},{"key":"key\n\t\t\t\t20170511081657_HYS215C38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease","volume":"4","author":"Dunstan","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C40","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C41","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170511081657_HYS215C42","first-page":"1259","article-title":"Discovery research on the effects of giving continuity to the administration of bortezomib in maintenance therapy to target of relapsed and refractory multiple myeloma","volume":"61","author":"Suzuki","year":"2012","journal-title":"J New Rem Clin"},{"key":"key\n\t\t\t\t20170511081657_HYS215C43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"10","author":"Gandhi","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"key\n\t\t\t\t20170511081657_HYS215C44","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C45","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t20170511081657_HYS215C46","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C47","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMe1202819","article-title":"Lenalidomide in myeloma\u2014a high-maintenance friend","volume":"366","author":"Badros","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C48","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C49","article-title":"Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment","author":"Armeson","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20170511081657_HYS215C50","first-page":"w13562","article-title":"Effective response with bortezomib retreatment in relapsed multiple myeloma\u2014a multicentre retrospective survey in Switzerland","volume":"142","author":"Taverna","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"key\n\t\t\t\t20170511081657_HYS215C51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2929.2929","article-title":"Long-term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len+Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)","author":"Dimopoulos","year":"2011"},{"key":"key\n\t\t\t\t20170511081657_HYS215C52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1877.1877","article-title":"Incidence and Characteristics of Secondary Myelodysplastic Syndrome Developing during Lenalidomide-based Regimens in Relapsed and\/or refractory Multiple Myeloma Patients","author":"Reece","year":"2010"},{"key":"key\n\t\t\t\t20170511081657_HYS215C53","first-page":"1264","article-title":"Therapy-related myelodysplastic syndrome\/acute myeloid leukemia in patients with multiple myeloma","volume":"52","author":"Abe","year":"2012","journal-title":"Rinsho Ketsueki"},{"key":"key\n\t\t\t\t20170511081657_HYS215C54","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blade","year":"1998","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170511081657_HYS215C55","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","article-title":"Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents","volume":"34","author":"Roussou","year":"2010","journal-title":"Leuk Res"},{"key":"key\n\t\t\t\t20170511081657_HYS215C56","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in MM according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170511081657_HYS215C57","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated V9 T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp Hematol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/43\/2\/116\/11660077\/hys215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T22:07:17Z","timestamp":1595196437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article-lookup\/doi\/10.1093\/jjco\/hys215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,4]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,1,4]]},"published-print":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hys215","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1,4]]}}}